Nuveen
LFCR icon

Nuveen’s Lifecore Biomedical LFCR Stock Holding History

Nuveen’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
52,928
+17,078
+48% +$86K ﹤0.01% 3528
2026
Q1 		$133K Hold
35,850
– – ﹤0.01% 3156
2025
Q4 		$293K Hold
35,850
– – ﹤0.01% 3051
2025
Q3 		$264K Hold
35,850
– – ﹤0.01% 3091
2025
Q2 		$291K Buy
35,850
+7,013
+24% +$47.3K ﹤0.01% 3067
2025
Q1 		$203K Hold
28,837
– – ﹤0.01% 3131
2024
Q4 		$214K Hold
28,837
– – ﹤0.01% 3193
2024
Q3 		$142K Hold
28,837
– – ﹤0.01% 3278
2024
Q2 		$148K Buy
+28,837
New +$171K ﹤0.01% 3271
2023
Q1 		– Sell
-90,357
Closed -$586K – 3127
2022
Q4 		$586K Sell
90,357
-13,508
-13% -$111K ﹤0.01% 2841
2022
Q3 		$924K Sell
103,865
-502
-0.5% -$5.1K ﹤0.01% 2787
2022
Q2 		$1.04M Sell
104,367
-8,042
-7% -$79.6K ﹤0.01% 2761
2022
Q1 		$1.24M Sell
112,409
-1,777
-2% -$19.8K ﹤0.01% 2723
2021
Q4 		$1.22M Sell
114,186
-32,192
-22% -$312K ﹤0.01% 2786
2021
Q3 		$1.35M Sell
146,378
-22,601
-13% -$246K ﹤0.01% 2856
2021
Q2 		$1.9M Buy
168,979
+18,929
+13% +$218K ﹤0.01% 2739
2021
Q1 		$1.59M Sell
150,050
-312,524
-68% -$3.51M ﹤0.01% 2717
2020
Q4 		$5.02M Buy
462,574
+332,295
+255% +$3.43M ﹤0.01% 2075
2020
Q3 		$1.27M Buy
130,279
+16,203
+14% +$154K ﹤0.01% 2585
2020
Q2 		$908K Buy
114,076
+13,064
+13% +$135K ﹤0.01% 2656
2020
Q1 		$878K Sell
101,012
-425
-0.4% -$4.42K ﹤0.01% 2565
2019
Q4 		$1.15M Sell
101,437
-449
-0.4% -$4.78K ﹤0.01% 2642
2019
Q3 		$1.11M Buy
101,886
+2,368
+2% +$25.8K ﹤0.01% 2658
2019
Q2 		$933K Buy
+99,518
New +$1M ﹤0.01% 2774

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Nuveen's LFCR Position: Q2 2026 in Review

Nuveen increased its Lifecore Biomedical (LFCR) stake by 48% in Q2 2026, buying an estimated $86K and bringing the position to 52,928 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #3528.

Nuveen first reported a position in LFCR in Q2 2019 and has held it in 24 quarters since. The position peaked at $5.02M in Q4 2020. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Nuveen held 52,928 shares of Lifecore Biomedical worth $278K as of Q2 2026.
  • Nuveen bought 17,078 Lifecore Biomedical shares in Q2 2026, an estimated $86K.
  • Lifecore Biomedical made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3528 holding.
  • Nuveen first reported a position in Lifecore Biomedical in Q2 2019 and has held it in 24 quarters since.
  • Nuveen's Lifecore Biomedical position peaked at $5.02M in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.